Baseline characteristic | Value (N = 187) |
---|---|
Age (years), median (range) | 36.4 (18–64) |
Gender, N (%) | |
Male | 108 (57.7%) |
Primary diagnosis, N (%) | |
Leukaemia | 77 (41.2%) |
Acute lymphoblastic leukaemia | 19 |
Acute myeloid leukaemia | 39 |
Chronic myeloid leukaemia | 7 |
Myelodysplastic syndrome | 12 |
Lymphoma | 66 (35.3%) |
Non-Hodgkin lymphoma | 24 |
Hodgkin lymphoma | 42 |
Other malignancies | 16 (8.5%) |
Multiple myeloma | 15 |
Germ-cell tumour | 1 |
Non-malignancies | 28 (14.9%) |
Aplastic anaemia | 14 |
Fanconi anaemia | 1 |
Myelofibrosis | 2 |
Red-cell aplasia | 1 |
Sickle-cell anaemia | 1 |
Thalassaemia | 9 |
Type of transplant | |
Autologous | 65 (34.8%) |
Allogeneic | 122 (65.2%) |
Related donor | 15 |
Unrelated donor | 105 |
Haplo-identical transplant | 2 |
Stem cell source, N (%) | |
Peripheral stem cells | 166 (88.8%) |
Bone marrow cells | 19 (10.1%) |
Bone marrow and peripheral stem cells | 1 (0.5%) |
Umbilical cord bank | 1 (0.5%) |
Conditioning regimen intensity, N (%) | |
Myeloablative | 130 (69.5%) |
Reduced intensity | 55 (29.4%) |
Reduced toxicity | 1 (0.5%) |
None | 1 (0.5%) |
Baseline comorbidity, N (%) | |
Cardiac disease | 40 (21.4%) |
Endocrine disease | 25 (13.3%) |
Kidney disease | 10 (5.3%) |
Liver disease | 6 (3.2%) |
Other | 43 (22.9%) |
GVHD, N (%) | |
Acute | 16 (8.6%) |
Chronic | 31 (16.6%) |
Both acute and chronic | 38 (20.3%) |
None | 102 (54.5%) |